Ask AI
ProCE Banner Activity

Aligning the Patient–Provider Therapeutic Connection to Improve Clinical Outcomes in Progressive HR+/HER2- Metastatic Breast Cancer

Slideset

These downloadable slides offer expert guidance on managing progressive HR-positive/HER2-negative metastatic breast cancer, including when and how to test for resistance mutations after progression on first-line CDK4/6 inhibitor therapy and how to use these results to guide next-line treatment. They also summarize the evolving evidence for oral SERDs, highlighting key mechanisms, clinical data, and practical counseling strategies to support patient understanding, self-management, and adherence.

Released: November 26, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients  

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Lilly, and Stemline Therapeutics, Inc.

AstraZeneca

Lilly

Stemline Therapeutics, Inc.

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for oncologists, nurse practitioners, physician associates, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan treatment for patients with HR+/HER2- MBC progressing on first-line endocrine therapy with or without CDK4/6 inhibitor based on individual patient and disease characteristics, genomic profile, available clinical data, new approvals, and expert recommendations

  • Mitigate and manage toxicities associated with oral SERD therapy for patients with HR+/HER2- breast cancer

  • Implement recommended strategies to improve adherence to oral SERD therapy in patients with HR+/HER2- breast cancer

  • Employ effective communication skills to equip patients with HR+/HER2- metastatic breast cancer with health self-efficacy so that they become partners in adherence to oral SERD therapy for the prescribed duration of treatment and in accurate reporting of treatment-related adverse events